Clinical Trials of Cancer Drugs Will Receive Funding of $6 Million

2002 ◽  
Vol 50 (6) ◽  
pp. 400
Keyword(s):  
Clinical Trials ◽  
Cancer Drugs

scholarly journals The Ambivalent Function of YAP in Apoptosis and Cancer

2018 ◽  
Vol 19 (12) ◽  
pp. 3770 ◽  
Author(s):  
Xianbin Zhang ◽  
Ahmed Abdelrahman ◽  
Brigitte Vollmar ◽  
Dietmar Zechner
Keyword(s):  
Clinical Trials ◽  
Signaling Pathway ◽  
Clinical Relevance ◽  
Protein A ◽  
Vital Role ◽  
Cancer Drugs ◽  
Good Target ◽  
Anti Cancer ◽  
The Future

Yes-associated protein, a core regulator of the Hippo-YAP signaling pathway, plays a vital role in inhibiting apoptosis. Thus, several studies and reviews suggest that yes-associated protein is a good target for treating cancer. Unfortunately, more and more evidence demonstrates that this protein is also an essential contributor of p73-mediated apoptosis. This questions the concept that yes-associated protein is always a good target for developing novel anti-cancer drugs. Thus, the aim of this review was to evaluate the clinical relevance of yes-associated protein for cancer pathophysiology. This review also summarized the molecules, processes and drugs, which regulate Hippo-YAP signaling and discusses their effect on apoptosis. In addition, issues are defined, which should be addressed in the future in order to provide a solid basis for targeting the Hippo-YAP signaling pathway in clinical trials.

Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review

2019 ◽  
Vol 20 (11) ◽  
pp. e619-e626 ◽  
Author(s):  
Ning Li ◽  
Hui-Yao Huang ◽  
Da-Wei Wu ◽  
Zhi-Min Yang ◽  
Jun Wang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Mainland China ◽  
Cancer Drugs

Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs

2020 ◽  
Vol 173 (4) ◽  
pp. 320-322 ◽  
Author(s):  
Samer Al Hadidi ◽  
Martha Mims ◽  
Courtney Nicole Miller-Chism ◽  
Rammurti Kamble
Keyword(s):  
Clinical Trials ◽  
African American ◽  
Drug Administration ◽  
Food And Drug Administration ◽  
Cancer Drugs

scholarly journals Anticancer Agents from Diverse Natural Sources

2014 ◽  
Vol 9 (11) ◽  
pp. 1934578X1400901 ◽  
Author(s):  
Jabeena Khazir ◽  
Darren L. Riley ◽  
Lynne A. Pilcher ◽  
Pieter De-Maayer ◽  
Bilal Ahmad Mir
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Anticancer Agents ◽  
Marine Organisms ◽  
New Drugs ◽  
Human Diseases ◽  
Cancer Drugs ◽  
Natural Sources ◽  
Anti Cancer ◽  
Ancient Times

This review attempts to portray the discovery and development of anticancer agents/drugs from diverse natural sources. Natural molecules from these natural sources including plants, microbes and marine organisms have been the basis of treatment of human diseases since the ancient times. Compounds derived from nature have been important sources of new drugs and also serve as templates for synthetic modification. Many successful anti-cancer drugs currently in use are naturally derived or their analogues and many more are under clinical trials. This review aims to highlight the invaluable role that natural products have played, and continue to play, in the discovery of anticancer agents.

scholarly journals Targeting the Calcium Signalling Machinery in Cancer

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2351 ◽  
Author(s):  
Jason I. E. Bruce ◽  
Andrew D. James
Keyword(s):  
Cell Proliferation ◽  
Clinical Trials ◽  
Cell Death ◽  
Therapeutic Strategy ◽  
Calcium Signalling ◽  
Cellular Migration ◽  
Cancer Drugs

Cancer is caused by excessive cell proliferation and a propensity to avoid cell death, while the spread of cancer is facilitated by enhanced cellular migration, invasion, and vascularization. Cytosolic Ca2+ is central to each of these important processes, yet to date, there are no cancer drugs currently being used clinically, and very few undergoing clinical trials, that target the Ca2+ signalling machinery. The aim of this review is to highlight some of the emerging evidence that targeting key components of the Ca2+ signalling machinery represents a novel and relatively untapped therapeutic strategy for the treatment of cancer.

scholarly journals Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions

2021 ◽  
Vol 17 (5) ◽  
pp. 265-271 ◽  
Author(s):  
Muhammad Awidi ◽  
Samer Al Hadidi
Keyword(s):  
Clinical Trials ◽  
Black Americans ◽  
Cancer Therapeutics ◽  
Fundamental Unit ◽  
Cancer Clinical Trials ◽  
Cancer Drugs ◽  
The Future

Low participation of Black Americans in cancer clinical trials is a well-established predicament. Many factors resulted in this current dilemma with racism being the fundamental unit. Here, we discuss some current challenges and proposed solutions to help in increasing the enrollment of Black Americans in cancer clinical trials. We suggest implementing the least acceptable race-specific percentage as a new bar that registrational clinical trials need to pass before cancer drugs approval. Clinical trials will continue to draw the future of cancer therapeutics in which we believe that a prompt improvement of Black Americans participation is warranted.

Sign in / Sign up

Export Citation Format

Share Document